Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod
September 21, 2017 at 03:19 AM EDT
FRANKFURT, Sept 21 (Reuters) - European regulators on Thursday granted market approval for Merck KGaA and Pfizer's immuno-oncology drug Bavencio to treat a rare and aggressive type of skin cancer called Merkel cell carcinoma.